TKI Therapy Based on Molecular Monitoring in Allogeneic-HSCT Recipients With Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia

Name: TKI Therapy Based on Molecular Monitoring in Allogeneic-HSCT Recipients With Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia
Published: 2013
License: Public Domain

Nanfang Hospital, Southern Medical University · 2013

ClinicalTrials.gov · Datasets · License: Public Domain · 2013

Open Source ↗

philadelphia chromosome positive acute lymphocytic leukemia, stem cell transplantation, minimal residual disease, philadelphia chromosome, acute lymphoblastic leukemia, allogeneic hematopoietic cell transplantation, tyrosine kinase inhibitor, interventional, phase2

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

TKI Therapy Based on Molecular Monitoring in Allogeneic-HSCT Recipients With Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia

Related documents